Actively Recruiting
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
Led by Dongzhimen Hospital, Beijing · Updated on 2024-06-11
1000
Participants Needed
2
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
CONDITIONS
Official Title
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute ischemic stroke within 7 days of symptom onset
- Age 18 years or older
- Patient who has received Suhexiang Pill treatment
- Patient or legally authorized representative has signed informed consent
You will not qualify if you...
- Allergy to Suhexiang Pill
- Known pregnancy or breastfeeding
- Conditions that make outcome assessment or follow-up unlikely
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Dongzhimen Hospital
Beijing, Beijing Municipality, China, 100700
Not Yet Recruiting
2
Dongzhimen Hospital
Beijing, Beijing Municipality, China, 100700
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here